


Crustecdysone

Cat. No.:	HY-N6979
CAS No.:	5289-74-7
Molecular Formula:	C ₂₇ H ₄₄ O ₇
Molecular Weight:	480.63
Target:	Caspase; Autophagy; Endogenous Metabolite
Pathway:	Apoptosis; Autophagy; Metabolic Enzyme/Protease
Storage:	4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (208.06 mM; Need ultrasonic)						
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg	
				1 mM	2.0806 mL	10.4030 mL	20.8060 mL
				5 mM	0.4161 mL	2.0806 mL	4.1612 mL
				10 mM	0.2081 mL	1.0403 mL	2.0806 mL
Please refer to the solubility information to select the appropriate solvent.							
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (4.33 mM); Clear solution						
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (4.33 mM); Clear solution						
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (4.33 mM); Clear solution						

BIOLOGICAL ACTIVITY

Description	Crustecdysone (20-Hydroxyecdysone) is a naturally occurring ecdysteroid hormone isolated from <i>Cyanotis arachnoides</i> C.B.Clarke which controls the ecdysis (moulting) and metamorphosis of arthropods, it inhibits caspase activity and induces autophagy via the 20E nuclear receptor complex, EcR-USP ^[1] . Crustecdysone exhibits regulatory or protective roles in the cardiovascular system ^[2] . Crustecdysone is an active metabolite of Ecdysone (α-Ecdysone; HY-N0179) ^[3]
IC ₅₀ & Target	Human Endogenous Metabolite

REFERENCES

-
- [1]. Liu H, et al. E93 predominantly transduces 20-hydroxyecdysone signaling to induce autophagy and caspase activity in *Drosophila* fat body. *Insect Biochem Mol Biol*. 2014 Feb;45:30-9.
- [2]. Phungphong S, et al. 20-Hydroxyecdysone attenuates cardiac remodeling in spontaneously hypertensive rats. *Steroids*. 2017 Oct;126:79-84.
- [3]. Minglei Lu, et al. Ecdysone Elicits Chronic Renal Impairment via Mineralocorticoid-Like Pathogenic Activities. *Cell Physiol Biochem*. 2018;49(4):1633-1645.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA